iRhythm Technologies (NASDAQ:IRTC) Price Target Raised to $225.00 at Wells Fargo & Company

iRhythm Technologies (NASDAQ:IRTC) had its target price boosted by Wells Fargo & Company from $220.00 to $225.00 in a report published on Tuesday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other research analysts have also issued reports on IRTC. Evercore ISI raised iRhythm Technologies from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $194.00 to $210.00 in a report on Monday, January 5th. Needham & Company LLC restated a “buy” rating and set a $244.00 price objective on shares of iRhythm Technologies in a research report on Monday. Loop Capital set a $220.00 target price on shares of iRhythm Technologies in a report on Friday, October 31st. JPMorgan Chase & Co. boosted their price target on shares of iRhythm Technologies from $190.00 to $240.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, BTIG Research increased their price target on shares of iRhythm Technologies from $195.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $219.23.

iRhythm Technologies Price Performance

Shares of NASDAQ:IRTC opened at $155.44 on Tuesday. iRhythm Technologies has a one year low of $92.52 and a one year high of $212.00. The stock has a market capitalization of $5.01 billion, a price-to-earnings ratio of -96.55 and a beta of 1.12. The company has a 50-day simple moving average of $176.47 and a 200-day simple moving average of $168.63. The company has a debt-to-equity ratio of 5.32, a quick ratio of 4.50 and a current ratio of 4.63.

iRhythm Technologies (NASDAQ:IRTC) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.30. The firm had revenue of $192.88 million for the quarter, compared to analysts’ expectations of $184.75 million. iRhythm Technologies had a negative return on equity of 41.86% and a negative net margin of 7.32%.The firm’s revenue for the quarter was up 30.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.26) EPS. On average, analysts predict that iRhythm Technologies will post -1.98 EPS for the current year.

Insider Activity at iRhythm Technologies

In other news, CEO Quentin S. Blackford sold 14,059 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $182.94, for a total transaction of $2,571,953.46. Following the sale, the chief executive officer owned 164,979 shares of the company’s stock, valued at $30,181,258.26. The trade was a 7.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patrick Michael Murphy sold 2,478 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $458,008.74. Following the completion of the sale, the insider owned 53,281 shares in the company, valued at approximately $9,847,927.23. This represents a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 24,817 shares of company stock worth $4,741,235 in the last ninety days. Corporate insiders own 0.68% of the company’s stock.

Institutional Trading of iRhythm Technologies

A number of institutional investors have recently bought and sold shares of IRTC. Tudor Investment Corp ET AL purchased a new position in shares of iRhythm Technologies in the third quarter valued at $3,439,800,000. Geode Capital Management LLC grew its stake in iRhythm Technologies by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 767,336 shares of the company’s stock valued at $118,154,000 after acquiring an additional 16,967 shares during the last quarter. Stephens Investment Management Group LLC increased its holdings in iRhythm Technologies by 6.2% during the 2nd quarter. Stephens Investment Management Group LLC now owns 552,916 shares of the company’s stock valued at $85,127,000 after acquiring an additional 32,334 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in iRhythm Technologies by 6,415.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 541,039 shares of the company’s stock valued at $93,053,000 after acquiring an additional 532,735 shares in the last quarter. Finally, Holocene Advisors LP raised its position in iRhythm Technologies by 51.2% during the third quarter. Holocene Advisors LP now owns 473,280 shares of the company’s stock worth $81,399,000 after acquiring an additional 160,186 shares during the last quarter.

iRhythm Technologies News Roundup

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Company-issued preliminary results and guidance: iRhythm said FY-2025 revenue will exceed prior guidance (~$740M) and expects FY-2026 revenue of $870–$880M (17%–18% growth) with an adjusted EBITDA margin of ~11.5%–12.5%; management highlighted record unit volume and first-time free cash flow positivity. GlobeNewswire release
• Positive Sentiment: Analyst upgrades/price-target increases: Wells Fargo raised its price target to $225 and set an “overweight” rating, implying a sizable upside from current levels. Needham reaffirmed a buy and maintained a $244 target. These moves add institutional support to the upside case. Benzinga (Wells Fargo / Needham)
• Neutral Sentiment: J.P. Morgan Healthcare Conference presentation: Management presented slides and a transcript (Q&A and strategic update). Useful for detail on expansion plans (primary care, AI risk stratification, adjacent markets) — may inform longer-term sentiment but not an immediate earnings release. Seeking Alpha slides Seeking Alpha transcript
• Neutral Sentiment: Analyst coverage and price-target consensus remain strongly positive (multiple buy/overweight ratings, median target near $212), which supports a longer-term bull case but leaves the stock exposed to near-term volatility. Quiver Quant summary
• Negative Sentiment: Insider selling: Quiver/GlobeNewswire data flagged extensive insider sales across several executives in recent months. Heavy insider selling can pressure sentiment and raise valuation/ timing concerns for some investors. Quiver Quant insider summary
• Neutral Sentiment: Short-interest note appears unreliable: a reported “increase” to 0 shares with NaN changes and 0 days-to-cover is inconsistent and not actionable; treat this as non-informative until clarified by exchange data. (No direct link provided.)

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.